Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
Markham, Ontario and Duren, Germany (ots/PRNewswire) - Acquisition Establishes Enghouse Networks Presence In Germany Enghouse Systems Limited (TSX: ENGH) announced today it has acquired XConnect GmbH, from XConnect Global Networks Ltd. Headquartered in Duren (outside of Cologne), XConnect GmbH provides carrier change processes and number portability services to telecommunication providers in Germany. Its software enables ...
Nuremberg, Germany (ots/PRNewswire) - When it comes to the factors that make up 'the good life', the top three most popular items selected by people internationally are good health, financial security and leisure time. These are followed by a happy marriage, travel for leisure, a home you own, and control over one's ...
Nuremberg, Germany (ots/PRNewswire) - - France leaps to second place for first time, while UK regains ground to remain third and Japan enters top five - USA is only country showing overall decline in 2017 - Germany major gains in Governance, People, and Culture In the wake of a substantial drop in global perception ...
Darmstadt, Germany (ots/PRNewswire) - - New pen is easy-to-learn and easy-to-use, supporting the one in six couples affected by infertility in the U.S.[1] - Insights of patients, nurses and doctors helped to evolve the product Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and ...
Darmstadt, Germany (ots/PRNewswire) - - First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe - Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years Merck, a leading science and technology company, today announced that the National Institute ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. based media. - Grant awarded across three research projects focused on prediction and defining characteristics of multiple sclerosis - Investment of EUR5 million in multiple sclerosis research funding as awards mark fifth year Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...
Darmstadt, Germany (ots/PRNewswire) - - Multiple sclerosis diagnosis has a profound impact on life choices including education, career, family planning and relationships - Almost 90% of women say multiple sclerosis played a role in their separation or divorce following diagnosis - Policy interventions could help address significant gender-specific challenges Merck, a ...
Nuremberg, Germany (ots/PRNewswire) - Factors rated "very" or "extremely" important by consumers Nearly half of consumers report that "low sugar or sugar-free" and "free from GMO ingredients" are very or extremely important factors when deciding which food or beverage product to eat or drink. These factors top the list, just ahead of factors such as low-salt, organic, ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...
Münster, Germany (ots/PRNewswire) - Comprehensive cooperation in terms of technology development, localized production and commercialization COMPO EXPERT GmbH (COMPO EXPERT), a leading manufacturer of specialty fertilizers for commercial use and portfolio company of the London-headquartered global private equity ...
Nuremberg, Germany (ots/PRNewswire) - One in three now include "take a break from technology" in their health routine. Nuremberg, September 28, 2017 - When it comes to which activities people do regularly to maintain their physical health, it is no surprise that nearly two thirds of the online population across 17 ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
Karlsruhe, Germany (ots) - - Cross reference: Picture is available at http://www.presseportal.de/pm/119247/3740239 - Cinemo's Unified Media Solution presented on a next generation In-Vehicle Infotainment (IVI) prototype Cinemo, a global leader in high performance and automotive grade multimedia playback, streaming, media management, connectivity and cloud access middleware, and Bosch Car Multimedia, a supplier of intelligent solutions, that help make the integration of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on areas of high unmet need to help enhance ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK/U.S. based media - EUR1 million grant funded by Merck supports research with the potential to advance implementation of personalized treatment for solid tumors - Three winners selected from 100 scientifically diverse applicants worldwide Merck, a leading ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. or U.S. based media ESMO 2017 abstract # Erbitux®: 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib (c-Met kinase inhibitor): 701P - Data to showcase Merck's strong and diverse pipeline ranging from ...
Darmstadt, Germany (ots/PRNewswire) - - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe - MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Marketing authorization includes the 28 countries of the European Union (EU), with first ...
Nuremberg, Germany (ots/PRNewswire) - - Garden centers should target people in their thirties and households with children under 12 years old, according to GfK Nearly a third of the online population across 17 countries does gardening or yard work either daily or weekly, according to data just published by GfK. This ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Decision secures access to Erbitux® for new patients in England with oral cavity tumors - All patients currently receiving Erbitux® will have continued access Merck, a leading science and technology company, announced today that the ...
Nuremberg, Germany (ots/PRNewswire) - On average, a quarter of people entertain guests in their home (http://www.gfk.com/global-studies/global-studies-frequency-of-entertaining-guests-at-home/) either daily or weekly, and a further third entertain monthly. Less than one in ten people say that they never entertain ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ...
Nuremberg, Germany (ots/PRNewswire) - - One in three people find it difficult to take a break from technology, even when they know they should - China, Brazil and Argentina have highest levels who struggle to take a tech break - People in Germany, The Netherlands and Belgium lead for finding it easy to 'unplug' A ...
Norderstedt, Germany (ots/PRNewswire) - The ECHELON FLEX(TM) GST System now features a 45mm endocutter intended for use in very thick tissue[5], making it suitable across a range of specialties Building on the success of the ECHELON FLEX(TM) 60mm Powered Plus Stapler with Gripping Surface Technology (GST), Ethicon*, a leading global provider of medical devices, today ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T lymphocytes, with lymphocyte counts returning to normal range before the end of Year 2 - The lymphocyte data presented at EAN Congress are consistent with other clinical safety ...
Darmstadt, Germany (ots/PRNewswire) - - New data builds on company's longstanding commitment to MS Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 3rd Congress of the European Academy of Neurology (EAN), taking place from June 24-27, in Amsterdam, ...
Darmstadt, Germany (ots/PRNewswire) - - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical ...